Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3
Published . Updated .
Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule could offer better tolerability compared to the rest of its class. The SPAC merger taking Corxel public is expected to close in the first half of 2027, which
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- LLY Eli Lilly and+11.9% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- JNJ Johnson & Johnson-0.9% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- PFE Pfizer+8.3% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- MRK Merck+0.3% 13d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -2.01% | -0.19% | base | +0.02% | after close | after close | after close |
| XBI | -1.12% | +2.16% | base | +0.66% | after close | after close | after close |
| LLY | -2.64% | -0.26% | base | +0.41% | after close | after close | after close |
| JNJ | -3.73% | -2.35% | base | +0.95% | after close | after close | after close |
| PFE | -1.93% | -0.50% | base | -0.73% | after close | after close | after close |
| MRK | -1.16% | +3.17% | base | -3.18% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3 MedCity News
Source: MedCity News
Select Sector Spdr Tr (XLV) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | that day | +0.95% | final price |
| Johnson & Johnson (JNJ) | three days earlier | -2.35% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -3.73% | final price |
| Eli Lilly (LLY) | that day | +0.41% | final price |
| Eli Lilly (LLY) | three days earlier | -0.26% | final price |
| Eli Lilly (LLY) | five days earlier | -2.64% | final price |
| Merck (MRK) | that day | -3.18% | final price |
| Merck (MRK) | three days earlier | +3.17% | final price |
| Merck (MRK) | five days earlier | -1.16% | final price |
| Pfizer (PFE) | that day | -0.73% | final price |
| Pfizer (PFE) | three days earlier | -0.50% | final price |
| Pfizer (PFE) | five days earlier | -1.93% | final price |
| Spdr Series Trust (XBI) | that day | +0.66% | final price |
| Spdr Series Trust (XBI) | three days earlier | +2.16% | final price |
| Spdr Series Trust (XBI) | five days earlier | -1.12% | final price |
| Select Sector Spdr Tr (XLV) | that day | +0.02% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.19% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.01% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 31 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 48 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 66 days before publication. Filed 8 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 31 Jul 2026. That is 87 days before publication. Filed 22 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 32 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 68 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, sold Merck (MRK), worth $250,001 - $500,000 on 31 Jul 2026. That is 87 days before publication. Filed 22 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies tied to this story
- XLV Select Sector Spdr Tr
For “Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- XBI Spdr Series Trust
In “Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- LLY Eli Lilly
For “Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 26 Oct 2026 story “Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- PFE Pfizer
In “Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- MRK Merck
In “Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
“Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3” (26 Oct 2026) reaches Select Sector Spdr Tr (XLV) through this story.
What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
The price range for Select Sector Spdr Tr (XLV), and the dates in the story
LLY traded between 1131.55 and 1321.17 across 20 sessions. The latest close on file is 1273.69. XBI traded between 152.63 and 158.97 across 2 sessions. The latest close on file is 154.01. XLV traded between 166.19 and 168.74 across 2 sessions. The latest close on file is 167.68.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.